Orbimed Advisors Llc - Net Worth and Insider Trading

Orbimed Advisors Llc Net Worth

The estimated net worth of Orbimed Advisors Llc is at least $3.7 Billion dollars as of 2024-06-05. Orbimed Advisors Llc is the Director, 10% Owner of Synthorx Inc and owns about 5,316,355 shares of Synthorx Inc (THOR) stock worth over $361 Million. Orbimed Advisors Llc is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Orbimed Advisors Llc is also the Director, 10% Owner of Edgewise Therapeutics Inc and owns about 14,756,096 shares of Edgewise Therapeutics Inc (EWTX) stock worth over $257 Million. Besides these, Orbimed Advisors Llc also holds Loxo Oncology Inc (LOXO) , SpringWorks Therapeutics Inc (SWTX) , Audentes Therapeutics Inc (BOLD) , Principia Biopharma Inc (PRNB) , Enliven Therapeutics Inc (ELVN) , Turning Point Therapeutics Inc (TPTX) , Relypsa Inc (RLYP) , Rhythm Pharmaceuticals Inc (RYTM) , Supernus Pharmaceuticals Inc (SUPN) , ARS Pharmaceuticals Inc (SPRY) , NxStage Medical Inc (NXTM) , Third Harmonic Bio Inc (THRD) , Pacira BioSciences Inc (PCRX) , Theseus Pharmaceuticals Inc (THRX) , Mirati Therapeutics Inc (MRTX) , CTI BioPharma Corp (CTIC) , Fusion Pharmaceuticals Inc (FUSN) , Intellia Therapeutics Inc (NTLA) , Keros Therapeutics Inc (KROS) , Silverback Therapeutics Inc (SBTX) , Verona Pharma PLC (VRNA) , Terns Pharmaceuticals Inc (TERN) , Prelude Therapeutics Inc (PRLD) , Dimension Therapeutics Inc (DMTX) , ArriVent BioPharma Inc (AVBP) , Imara Inc (IMRA) , Compass Therapeutics Inc (CMPX) , CalciMedica Inc (CALC) , scPharmaceuticals Inc (SCPH) , NeuroPace Inc (NPCE) , Intercept Pharmaceuticals Inc (ICPT) , ORIC Pharmaceuticals Inc (ORIC) , Alpine Immune Sciences Inc (ALPN) , TELA Bio Inc (TELA) , Adicet Bio Inc (ACET) , 89bio Inc (ETNB) , Corvus Pharmaceuticals Inc (CRVS) , Constellation Pharmaceuticals Inc (CNST) , SI-BONE Inc (SIBN) , Janux Therapeutics Inc (JANX) , PMV Pharmaceuticals Inc (PMVP) , Passage Bio Inc (PASG) , Alector Inc (ALEC) , Turnstone Biologics Corp (TSBX) , Disc Medicine Inc (IRON) , Adaptimmune Therapeutics PLC (ADAP) , Decibel Therapeutics Inc (DBTX) , NextCure Inc (NXTC) , Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , Cartesian Therapeutics Inc (RNAC) , Spyre Therapeutics Inc (SYRE) , resTORbio Inc (TORC) , Kinnate Biopharma Inc (KNTE) , Galecto Inc (GLTO) , Aerpio Pharmaceuticals Inc (ARPO) , LogicBio Therapeutics Inc (LOGC) , Kala Bio Inc (KALA) , Acutus Medical Inc (AFIB) , Repare Therapeutics Inc (RPTX) , Inspire Medical Systems Inc (INSP) , Ikena Oncology Inc (IKNA) , Otonomy Inc (OTIC) , Pieris Pharmaceuticals Inc (PIRS) , Sientra Inc (SIENQ) , ViewRay Inc (VRAYQ) , Logic Devices Inc (LOGC) , Athersys Inc (ATHXQ) , Sorrento Tech Inc (ROKA) , SteadyMed Ltd (STDY) , Glaukos Corp (GKOS) , Tricida Inc (TCDAQ) . Details can be seen in Orbimed Advisors Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Orbimed Advisors Llc has not made any transactions after 2024-05-16 and currently still holds the listed stock(s).

Transaction Summary of Orbimed Advisors Llc

To

Orbimed Advisors Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Orbimed Advisors Llc owns 92 companies in total, including Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , and LogicBio Therapeutics Inc (LOGC) among others .

Click here to see the complete history of Orbimed Advisors Llc’s form 4 insider trades.

Insider Ownership Summary of Orbimed Advisors Llc

Ticker Comapny Transaction Date Type of Owner
ARQT Arcutis Biotherapeutics Inc 2022-06-24 director & 10 percent owner
XTNT Xtant Medical Holdings Inc 2018-02-14 10 percent owner
LOGC LogicBio Therapeutics Inc 2020-10-01 director & 10 percent owner
LIMIT LIMIT 2020-09-25 director & 10 percent owner
LIMIT LIMIT 2023-05-22 director & 10 percent owner
LIMIT LIMIT 2023-11-22 10 percent owner
LIMIT LIMIT 2022-01-26 director & 10 percent owner
LIMIT LIMIT 2020-08-18 director
LIMIT LIMIT 2021-07-19 director & 10 percent owner
LIMIT LIMIT 2020-07-16 10 percent owner
LIMIT LIMIT 2020-06-30 director
LIMIT LIMIT 2021-09-07 director
LIMIT LIMIT 2022-11-25 10 percent owner
LIMIT LIMIT 2021-03-30 director
LIMIT LIMIT 2020-04-16 10 percent owner
LIMIT LIMIT 2020-04-13 director
LIMIT LIMIT 2021-07-16 director & 10 percent owner
LIMIT LIMIT 2021-01-07 10 percent owner
LIMIT LIMIT 2023-06-28 10 percent owner
LIMIT LIMIT 2019-11-22 director & 10 percent owner
LIMIT LIMIT 2022-11-25 director & 10 percent owner
LIMIT LIMIT 2023-04-21 10 percent owner
LIMIT LIMIT 2022-09-12 10 percent owner
LIMIT LIMIT 2021-09-20 director
LIMIT LIMIT 2019-06-24 director & 10 percent owner
LIMIT LIMIT 2019-05-21 10 percent owner
LIMIT LIMIT 2019-05-13 director & 10 percent owner
LIMIT LIMIT 2019-04-22 director
LIMIT LIMIT 2019-02-19 10 percent owner
LIMIT LIMIT 2023-12-28 director
LIMIT LIMIT 2018-12-11 director & 10 percent owner
LIMIT LIMIT 2018-10-19 director
LIMIT LIMIT 2018-10-03 10 percent owner
LIMIT LIMIT 2018-09-26 10 percent owner
LIMIT LIMIT 2018-08-30 10 percent owner
LIMIT LIMIT 2018-08-20 director & 10 percent owner
LIMIT LIMIT 2018-07-23 10 percent owner
LIMIT LIMIT 2018-07-17 10 percent owner
LIMIT LIMIT 2020-12-08 director & 10 percent owner
LIMIT LIMIT 2018-06-22 director & 10 percent owner
LIMIT LIMIT 2018-06-06 director
LIMIT LIMIT 2018-05-22 10 percent owner
LIMIT LIMIT 2018-04-30 director & 10 percent owner
LIMIT LIMIT 2018-03-12 10 percent owner
LIMIT LIMIT 2018-03-06 director
LIMIT LIMIT 2018-02-08 10 percent owner & other: See Remarks
LIMIT LIMIT 2017-08-28 director
LIMIT LIMIT 2017-12-08 director
LIMIT LIMIT 2017-11-15 10 percent owner
LIMIT LIMIT 2017-10-03 10 percent owner
LIMIT LIMIT 2017-02-21 10 percent owner
LIMIT LIMIT 2016-12-30 director & 10 percent owner
LIMIT LIMIT 2016-11-29 director & 10 percent owner
LIMIT LIMIT 2016-07-25 10 percent owner
LIMIT LIMIT 2016-06-27 director & 10 percent owner
LIMIT LIMIT 2016-05-11 10 percent owner
LIMIT LIMIT 2015-11-30 director
LIMIT LIMIT 2015-10-27 director & 10 percent owner
LIMIT LIMIT 2015-10-12 10 percent owner
LIMIT LIMIT 2015-03-26 director & 10 percent owner
LIMIT LIMIT 2014-07-01 10 percent owner
LIMIT LIMIT 2013-09-24 other: Former 10% Owner
LIMIT LIMIT 2013-02-13 10 percent owner
LIMIT LIMIT 2013-01-30 director
LIMIT LIMIT 2011-01-01 director & 10 percent owner
LIMIT LIMIT 2012-03-12 10 percent owner
LIMIT LIMIT 2012-02-08 10 percent owner
LIMIT LIMIT 2011-04-26 director & other: (1)
LIMIT LIMIT 2010-12-09 director
LIMIT LIMIT 2010-04-30 10 percent owner
LIMIT LIMIT 2007-05-10 10 percent owner
LIMIT LIMIT 2009-05-22 10 percent owner
LIMIT LIMIT 2007-05-14 director
LIMIT LIMIT 2017-03-15 director & 10 percent owner
LIMIT LIMIT 2024-05-03 10 percent owner
LIMIT LIMIT 2021-02-17 10 percent owner
LIMIT LIMIT 2023-05-15 director & 10 percent owner
LIMIT LIMIT 2020-12-08 director & 10 percent owner
LIMIT LIMIT 2024-01-23 director & 10 percent owner
LIMIT LIMIT 2024-01-25 director & 10 percent owner
LIMIT LIMIT 2022-11-08 director & 10 percent owner
LIMIT LIMIT 2023-07-17 director & 10 percent owner
LIMIT LIMIT 2023-05-05 director
LIMIT LIMIT 2023-08-15 director & 10 percent owner
LIMIT LIMIT 2023-12-18 director & 10 percent owner
LIMIT LIMIT 2021-12-29 director
LIMIT LIMIT 2022-12-23 director & 10 percent owner
LIMIT LIMIT 2021-03-30 director
LIMIT LIMIT 2022-09-19 director & 10 percent owner
LIMIT LIMIT 2023-08-29 director
LIMIT LIMIT 2024-05-16 director & 10 percent owner
LIMIT LIMIT 2023-07-20 director & 10 percent owner

Orbimed Advisors Llc Latest Holdings Summary

Orbimed Advisors Llc currently owns a total of 75 stocks. Among these stocks, Orbimed Advisors Llc owns 5,316,355 shares of Synthorx Inc (THOR) as of December 11, 2018, with a value of $361 Million and a weighting of 9.87%. Orbimed Advisors Llc owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 8.68%. Orbimed Advisors Llc also owns 14,756,096 shares of Edgewise Therapeutics Inc (EWTX) as of January 23, 2024, with a value of $257 Million and a weighting of 7.03%. The other 72 stocks Loxo Oncology Inc (LOXO) , SpringWorks Therapeutics Inc (SWTX) , Audentes Therapeutics Inc (BOLD) , Principia Biopharma Inc (PRNB) , Enliven Therapeutics Inc (ELVN) , Turning Point Therapeutics Inc (TPTX) , Relypsa Inc (RLYP) , Rhythm Pharmaceuticals Inc (RYTM) , Supernus Pharmaceuticals Inc (SUPN) , ARS Pharmaceuticals Inc (SPRY) , NxStage Medical Inc (NXTM) , Third Harmonic Bio Inc (THRD) , Pacira BioSciences Inc (PCRX) , Theseus Pharmaceuticals Inc (THRX) , Mirati Therapeutics Inc (MRTX) , CTI BioPharma Corp (CTIC) , Fusion Pharmaceuticals Inc (FUSN) , Intellia Therapeutics Inc (NTLA) , Keros Therapeutics Inc (KROS) , Silverback Therapeutics Inc (SBTX) , Verona Pharma PLC (VRNA) , Terns Pharmaceuticals Inc (TERN) , Prelude Therapeutics Inc (PRLD) , Dimension Therapeutics Inc (DMTX) , ArriVent BioPharma Inc (AVBP) , Imara Inc (IMRA) , Compass Therapeutics Inc (CMPX) , CalciMedica Inc (CALC) , scPharmaceuticals Inc (SCPH) , NeuroPace Inc (NPCE) , Intercept Pharmaceuticals Inc (ICPT) , ORIC Pharmaceuticals Inc (ORIC) , Alpine Immune Sciences Inc (ALPN) , TELA Bio Inc (TELA) , Adicet Bio Inc (ACET) , 89bio Inc (ETNB) , Corvus Pharmaceuticals Inc (CRVS) , Constellation Pharmaceuticals Inc (CNST) , SI-BONE Inc (SIBN) , Janux Therapeutics Inc (JANX) , PMV Pharmaceuticals Inc (PMVP) , Passage Bio Inc (PASG) , Alector Inc (ALEC) , Turnstone Biologics Corp (TSBX) , Disc Medicine Inc (IRON) , Adaptimmune Therapeutics PLC (ADAP) , Decibel Therapeutics Inc (DBTX) , NextCure Inc (NXTC) , Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , Cartesian Therapeutics Inc (RNAC) , Spyre Therapeutics Inc (SYRE) , resTORbio Inc (TORC) , Kinnate Biopharma Inc (KNTE) , Galecto Inc (GLTO) , Aerpio Pharmaceuticals Inc (ARPO) , LogicBio Therapeutics Inc (LOGC) , Kala Bio Inc (KALA) , Acutus Medical Inc (AFIB) , Repare Therapeutics Inc (RPTX) , Inspire Medical Systems Inc (INSP) , Ikena Oncology Inc (IKNA) , Otonomy Inc (OTIC) , Pieris Pharmaceuticals Inc (PIRS) , Sientra Inc (SIENQ) , ViewRay Inc (VRAYQ) , Logic Devices Inc (LOGC) , Athersys Inc (ATHXQ) , Sorrento Tech Inc (ROKA) , SteadyMed Ltd (STDY) , Glaukos Corp (GKOS) , Tricida Inc (TCDAQ) have a combined weighting of 74.42% among all his current holdings.

Latest Holdings of Orbimed Advisors Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
THOR Synthorx Inc 2018-12-11 5,316,355 67.99 361,458,976
PRVL Prevail Therapeutics Inc 2019-06-24 13,822,463 23.00 317,916,649
EWTX Edgewise Therapeutics Inc 2024-01-23 14,756,096 17.44 257,346,314
LOXO Loxo Oncology Inc 2017-12-08 941,000 234.66 220,815,060
SWTX SpringWorks Therapeutics Inc 2022-09-12 5,599,842 38.91 217,889,852
BOLD Audentes Therapeutics Inc 2018-03-12 3,539,997 59.97 212,293,620
PRNB Principia Biopharma Inc 2019-05-21 1,605,713 100.05 160,651,586
ELVN Enliven Therapeutics Inc 2024-05-16 7,663,349 20.93 160,393,895
TPTX Turning Point Therapeutics Inc 2019-04-22 2,027,550 76.01 154,114,076
RLYP Relypsa Inc 2016-07-25 3,356,400 31.99 107,371,236
RYTM Rhythm Pharmaceuticals Inc 2018-05-22 2,750,079 38.58 106,098,048
SUPN Supernus Pharmaceuticals Inc 2013-02-13 3,000,000 27.92 83,760,000
SPRY ARS Pharmaceuticals Inc 2023-08-29 9,240,887 8.94 82,613,530
NXTM NxStage Medical Inc 2010-12-09 2,690,476 30.00 80,714,280
THRD Third Harmonic Bio Inc 2022-09-19 5,779,071 13.26 76,630,481
PCRX Pacira BioSciences Inc 2012-03-12 2,446,000 30.52 74,651,920
THRX Theseus Pharmaceuticals Inc 2023-07-17 17,713,600 4.06 71,917,216
MRTX Mirati Therapeutics Inc 2014-07-01 1,167,000 58.70 68,502,900
CTIC CTI BioPharma Corp 2021-01-07 7,520,600 9.09 68,362,254
FUSN Fusion Pharmaceuticals Inc 2020-06-30 3,122,770 21.55 67,295,694
NTLA Intellia Therapeutics Inc 2016-05-11 2,662,180 23.25 61,895,685
KROS Keros Therapeutics Inc 2020-04-13 1,119,812 49.53 55,464,288
SBTX Silverback Therapeutics Inc 2020-12-08 8,740,888 5.87 51,309,013
VRNA Verona Pharma PLC 2023-05-15 3,777,778 12.10 45,711,114
TERN Terns Pharmaceuticals Inc 2022-12-23 7,619,135 5.88 44,800,514
PRLD Prelude Therapeutics Inc 2023-05-22 10,646,056 3.56 37,899,959
DMTX Dimension Therapeutics Inc 2015-10-27 5,397,698 5.95 32,116,303
AVBP ArriVent BioPharma Inc 2024-01-30 1,513,664 18.33 27,745,461
IMRA Imara Inc 2021-07-16 4,199,068 6.32 26,538,110
CMPX Compass Therapeutics Inc 2022-11-08 18,791,422 1.34 25,180,505
CALC CalciMedica Inc 2020-09-25 4,163,347 5.63 23,418,827
SCPH scPharmaceuticals Inc 2022-11-25 5,559,528 4.02 22,349,303
NPCE NeuroPace Inc 2024-05-03 3,406,335 6.47 22,038,987
ICPT Intercept Pharmaceuticals Inc 2015-03-26 1,120,324 19.00 21,286,156
ORIC ORIC Pharmaceuticals Inc 2021-03-30 2,212,571 8.66 19,160,865
ALPN Alpine Immune Sciences Inc 2023-12-28 264,315 64.97 17,172,546
TELA TELA Bio Inc 2023-04-21 2,835,542 5.71 16,190,945
ACET Adicet Bio Inc 2024-01-25 11,447,140 1.36 15,568,110
ETNB 89bio Inc 2022-01-26 1,829,436 8.30 15,184,319
CRVS Corvus Pharmaceuticals Inc 2021-09-20 6,943,654 2.16 14,998,293
CNST Constellation Pharmaceuticals Inc 2018-07-23 417,921 33.99 14,205,135
SIBN SI-BONE Inc 2018-10-19 985,368 13.75 13,548,810
JANX Janux Therapeutics Inc 2021-12-29 231,098 48.52 11,212,875
PMVP PMV Pharmaceuticals Inc 2023-11-22 6,475,291 1.71 11,072,748
PASG Passage Bio Inc 2023-06-28 8,034,000 1.24 9,962,160
ALEC Alector Inc 2020-04-16 1,906,718 4.77 9,095,045
TSBX Turnstone Biologics Corp 2023-07-20 3,099,265 2.81 8,708,935
IRON Disc Medicine Inc 2023-12-18 224,405 36.57 8,206,491
ADAP Adaptimmune Therapeutics PLC 2018-06-06 4,901,310 1.01 4,950,323
DBTX Decibel Therapeutics Inc 2021-02-17 883,418 4.91 4,337,582
NXTC NextCure Inc 2019-05-13 2,711,013 1.35 3,659,868
ARQT Arcutis Biotherapeutics Inc 2022-06-24 415,142 7.88 3,271,319
XTNT Xtant Medical Holdings Inc 2018-02-14 3,316,128 0.72 2,371,032
RNAC Cartesian Therapeutics Inc 2016-06-27 60,847 35.77 2,176,497
SYRE Spyre Therapeutics Inc 2017-02-21 58,781 34.10 2,004,432
TORC resTORbio Inc 2018-01-30 690,055 2.28 1,573,325
KNTE Kinnate Biopharma Inc 2023-05-05 450,000 2.65 1,192,500
GLTO Galecto Inc 2023-08-15 1,510,375 0.54 808,051
ARPO Aerpio Pharmaceuticals Inc 2020-12-08 346,265 2.20 761,783
LOGC LogicBio Therapeutics Inc 2020-10-01 296,296 2.07 613,333
KALA Kala Bio Inc 2018-02-08 68,957 6.74 464,501
AFIB Acutus Medical Inc 2021-07-19 6,553,408 0.05 349,297
RPTX Repare Therapeutics Inc 2021-09-07 96,190 3.53 339,551
INSP Inspire Medical Systems Inc 2020-08-18 1,784 148.42 264,781
IKNA Ikena Oncology Inc 2021-03-30 130,924 1.74 227,808
OTIC Otonomy Inc 2015-11-30 1,850,094 0.01 15,726
PIRS Pieris Pharmaceuticals Inc 2018-04-30 486 10.30 5,005
SIENQ Sientra Inc 2015-10-12 178,500 0.03 4,820
VRAYQ ViewRay Inc 2018-08-20 69,617 0.00 1
LOGC Logic Devices Inc 2018-10-23 6,466,783 0.00 0
ATHXQ Athersys Inc 2011-04-26 0 0.00 0
ROKA Sorrento Tech Inc 2017-10-03 0 0.65 0
STDY SteadyMed Ltd 2018-08-30 0 4.73 0
GKOS Glaukos Corp 2018-03-06 0 111.63 0
TCDAQ Tricida Inc 2022-11-25 0 0.00 0

Holding Weightings of Orbimed Advisors Llc


Orbimed Advisors Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 0 transactions in Synthorx Inc (THOR) over the past 5 years. The most-recent trade in Synthorx Inc is the acquisition of 1,363,636 shares on December 11, 2018, which cost Orbimed Advisors Llc around $15 Million.

According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 1 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Orbimed Advisors Llc around $15 Million.

According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 4 transactions in Edgewise Therapeutics Inc (EWTX) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Edgewise Therapeutics Inc is the acquisition of 454,545 shares on January 23, 2024, which cost Orbimed Advisors Llc around $5 Million.

More details on Orbimed Advisors Llc's insider transactions can be found in the Insider Trading History of Orbimed Advisors Llc table.

Insider Trading History of Orbimed Advisors Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Orbimed Advisors Llc Trading Performance

GuruFocus tracks the stock performance after each of Orbimed Advisors Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Orbimed Advisors Llc is 9.2%. GuruFocus also compares Orbimed Advisors Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Orbimed Advisors Llc within 3 months outperforms 64 times out of 117 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Orbimed Advisors Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Orbimed Advisors Llc

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
38 out of 107 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.27 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 2.75 LIMIT LIMIT LIMIT LIMIT LIMIT

Orbimed Advisors Llc Ownership Network

Ownership Network List of Orbimed Advisors Llc

No Data

Ownership Network Relation of Orbimed Advisors Llc

Insider Network Chart

Orbimed Advisors Llc Owned Company Details

What does Arcutis Biotherapeutics Inc do?

Who are the key executives at Arcutis Biotherapeutics Inc?

Orbimed Advisors Llc is the director & 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include See Remarks Patrick Burnett , SVP and General Counsel Masaru Matsuda , and Chief Commercial Officer Larry Todd Edwards .

Arcutis Biotherapeutics Inc (ARQT) Insider Trades Summary

Over the past 18 months, Orbimed Advisors Llc made no insider transaction in Arcutis Biotherapeutics Inc (ARQT). Other recent insider transactions involving Arcutis Biotherapeutics Inc (ARQT) include a net sale of 42,938 shares made by Todd Franklin Watanabe , a net sale of 91,496 shares made by Patrick Burnett , and a net sale of 15,665 shares made by Masaru Matsuda .

In summary, during the past 3 months, insiders sold 115,402 shares of Arcutis Biotherapeutics Inc (ARQT) in total and bought 0 shares, with a net sale of 115,402 shares. During the past 18 months, 214,195 shares of Arcutis Biotherapeutics Inc (ARQT) were sold and 102,515 shares were bought by its insiders, resulting in a net sale of 111,680 shares.

Arcutis Biotherapeutics Inc (ARQT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Arcutis Biotherapeutics Inc Insider Transactions

No Available Data

Orbimed Advisors Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Orbimed Advisors Llc. You might contact Orbimed Advisors Llc via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.

Discussions on Orbimed Advisors Llc

No discussions yet.